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Objectives. This retrospective study was undertaken to provide
information on occurrence, risk prediction and prevention of
syncope in patients with an implantable cardioverter-defibrillator
(ICD).
Background. ICDs effectively terminate ventricular tachycardia
and fibrillation (VT/VF). Incapacitating symptoms, such as syn-
cope, may still occur.
Methods. We performed a retrospective analysis of data from
421 patients (clinical history, outpatient chart reviews and epi-
sode data) with mean (6SD) follow-up of 26 6 18 months.
Results. Of 421 patients, 229 (54.4%) had recurrent VT/VF, and
62 (14.7%) had syncope. The actuarial survival rate free of VT/VF
was 58%, 45% and 37% and that for survival free of syncope was
90%, 85% and 81% at 12, 24 and 36 months after implantation,
respectively. Once VT/VF had occurred, 76%, 68% and 62% of
patients remained free of syncope during the following 12, 24 and
36 months, and 68%, 64% and 56% remained free of second
syncope 12, 24 and 36 months after first syncope, respectively. In
cases of syncope, the mean cycle length (CL) of VT was 251 6
56 ms. A low baseline left ventricular ejection fraction (LVEF),
induction of fast VT (CL <300 ms) during programmed ventric-
ular stimulation and chronic atrial fibrillation (AF) were associ-
ated with an increased risk of syncope. If the LVEF was >40%,
fast VT had not been induced, and patients had no chronic AF;
96%, 92% and 92% of patients remained free of syncope after 12,
24 and 36 months, respectively. Once patients had a VT recur-
rence, syncope during the first VT and a high VT rate were the
strongest risk predictors of future syncope.
Conclusions. Identification of patients with an ICD with a low
and high risk of syncope seems to be feasible and might help as a
guide to driving restrictions in such patients.
(J Am Coll Cardiol 1998;31:608–15)
©1998 by the American College of Cardiology
Implantable cardioverter-defibrillators (ICDs) terminate ven-
tricular tachycardia (VT) and ventricular fibrillation (VF) with
high efficiency and reduce the rate of sudden cardiac death in
patients with otherwise fatal arrhythmias (1–3). However,
incapacitating symptoms, such as presyncope or syncope, may
still occur. They may cause harm to patients and others and
imply restrictions in the everyday lives of patients with an ICD,
of which the ban on driving has been of considerable social
interest and has been highlighted in many recent publications
(4–8). Recommendations by cardiologists on driving restric-
tions vary between institutions and countries, and even the
attendees of the two largest conferences on safety issues
related to driving and arrhythmias† and the study group on
ICD and Driving of the Working Groups on Cardiac Pacing
and Arrhythmias of the European Society of Cardiology felt
constrained by limitations of the available data with which to
make recommendations (8–11).
Fatal accidents caused by patients during ICD therapy
nevertheless seem to be infrequent (5,12). However, accidents
may be underreported for various reasons. Liberalization of
driving restrictions may better be justified if those patients with
a high risk of incapacitating symptoms could be identified.
Therefore, this retrospective study was undertaken to provide
data on the occurrence and prediction of risk for syncope in
patients with an ICD (13).
Methods
Patients. Data were retrospectively analyzed from 421
consecutive patients who received an ICD under current
guidelines for ICD implantation at our institution (University
of Mu¨nster) between July 1988 and January 1995 (14,15).
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Patient characteristics as well as implantation and hospital
discharge data had been prospectively collected in an ICD
database (Table 1). Outpatient charts were reviewed for
appropriate ICD therapy, appropriate shocks, occurrence of
syncope and measures taken to avoid recurrence of syncope.
Prophylactic indications for ICD implantation were excluded
from analysis.
All patients underwent coronary angiography and pro-
grammed ventricular stimulation (PVS) without antiarrhyth-
mic therapy or with amiodarone before ICD implantation.
PVS was performed according to the protocol presented
elsewhere (16,17). Predischarge PVS was performed in 333
patients (79%) according to the same protocol.
Devices that allowed for documentation of VT intervals and
intracardiac electrograms were implanted in 264 patients
(62.7%), for documentation of VT intervals in 141 (33.5%)
and for stored therapy counts only in 16 (3.8%). Shock energy
was first programmed to a maximum of 34 J, regardless of
defibrillation threshold (DFT). Antitachycardia pacing, when
programmed, started with 3 and ended with 10 stimuli, with a
first coupling interval of 81%.
Follow-up. Patients visited the ICD outpatient clinic rou-
tinely every 3 months and were encouraged to schedule
additional visits if first shocks, clusters of shocks or syncope
had occurred. Patients who were no longer followed up at our
or an affiliated clinic were censored at the last visit to our or the
affiliated clinic because the quality of follow-up of other
centers could not be checked, and thus events might have been
underestimated.
At each visit, arrhythmia-related symptoms, such as palpi-
tation, dizziness, presyncope and syncope, were documented,
and printouts of arrhythmias were obtained. Recurrence of VT
was assumed if patients reported regular palpitations of sud-
den onset, presyncope or syncope (ICDs with stored therapy
counts); stored tachycardia RR intervals were short (,250 ms)
or decreased suddenly at the onset of tachycardia and were
stable (ICDs with stored RR intervals); or the configuration of
stored electrograms was different from that during sinus
rhythm (ICDs with intracardiac electrograms); and if ICD
therapy, especially antitachycardia pacing, successfully termi-
nated the tachycardia. Syncope was defined as a short loss of
consciousness, either reported by the patient or a witness. In
patients who reported syncope and had no VT documented in
the ICD, the detection rate was reduced for 6 months, and 24-h
Holter monitoring and tilt-table testing were performed.
Abbreviations and Acronyms
AF 5 atrial fibrillation
CAD 5 coronary artery disease
CL 5 cycle length
DCM 5 dilated cardiomyopathy
DFT 5 defibrillation threshold
ICD 5 implantable cardioverter- defibrillator
LVEF 5 left ventricular ejection fraction
PVS 5 programmed ventricular stimulation
VT 5 ventricular tachycardia
VF 5 ventricular fibrillation
Table 1. Baseline Characteristics of Patients
Gender
Male 323 (76.7%)
Female 98 (23.3%)
Age (yr)
Mean 6 SD 58 6 13
Range 17–83
Heart disease
CAD 260 (61.8%)
DCM 87 (20.7%)
ARVD 23 (5.5%)
Valvular disease 17 (4.0%)
Other 19 (4.4%)
None 15 (3.6%)
NYHA functional class
I 92 (21.9%)
II 189 (44.9%)
III 140 (33.2%)
LVEF (%)
Mean 6 SD 43 6 17
Range 7–85
Atrial fibrillation 116 (27.6%)
Chronic 31 (7.4%)
Intermittent 85 (20.1%)
History of
Cardiac arrest 164 (39.0%)
VT 135 (32.1%)
Cardiac arrest1VT 122 (28.9%)
PVS at baseline
No VT/VF inducible 125 (29.7%)
VT inducible
CL $300 ms 115 (27.3%)
CL ,300 ms 133 (31.6%)
VF inducible 48 (11.4%)
PVS at discharge
No VT/VF inducible 136 (32.3%)
VT inducible
CL $300 ms 76 (18.1%)
CL ,300 ms 108 (25.7%)
VF inducible 11 (2.6%)
ICD (therapy zones)
One (shock-only devices) 220 (52.3%)
Two or three (shock1ATP) 201 (47.7%)
Detection rate (beats/min)
Mean 6 SD 177 6 25
Range 110–210
Medication at discharge
Class I antiarrhythmic agents 12 (2.4%)
Beta-blockers 75 (17.8%)
Amiodarone 32 (7.6%)
Sotalol 59 (14.0%)
Ca antagonists 22 (5.2%)
Digitalis 232 (55.1%)
Data presented are number (%) of patients, unless otherwise indicated.
ARVD 5 arrhythmogenic right ventricular disease; ATP 5 antitachycardia
pacing; CAD 5 coronary artery disease; CL 5 cycle length; DCM 5 dilated
cardiomyopathy; ICD 5 implantable cardioverter-defibrillator; LVEF 5 left
ventricular ejection fraction; NYHA 5 New York Heart Association; PVS 5
programmed ventricular stimulation; VF 5 ventricular fibrillation; VT 5
ventricular tachycardia.
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At the time of implantation and during follow-up, all
patients were informed about the risk of incapacitating symp-
toms, and recommendations concerning dangerous occupa-
tions were provided. The legal consequences of an accident
caused by a patient with a VT and an ICD were not well
defined before this study was performed. Therefore, we rec-
ommended that patients should not drive.
Statistical analysis. Standard deviation was used as the
index of dispersion of continuous variables. Mean values in two
groups were compared by the Mann-Whitney test.
The probability of VT- and syncope-free survival was
calculated according to the Kaplan-Meier method and was
measured from the date of implantation, first VT or first
syncope to the event (first VT, first and second syncope) or last
follow-up visit (18). Differences between pairs of actuarial
survival curves were tested by the log-rank test. A two-tailed
probability value #0.05 was regarded as significant.
Cox regression analysis was performed for patient baseline
characteristics to investigate the influence of different vari-
ables. For continuous variables, the hazard for an increase of 1
in the value of the covariate was calculated from the regression
coefficient b: exp(b). For binary variables, the hazard ratio for
the presence of a certain characteristic was calculated as
exp(b), where b is the regression coefficient.
Because patients were not randomly assigned to different
drugs, any retrospective univariate analysis of the effect of
drugs on the risk of syncope must be viewed with caution and
is meant only to provide some insight into the prevention of
syncope and to aid the design of future prospective syncope
prevention trials. Drug regimes during follow-up changed
considerably, according to the clinical history of the patients.
Because the inclusion of drug regimes would have violated two
strong assumptions of the Cox model—1) the effects of differ-
ent variables must be constant over time, and 2) variables must
be independent and additive—drugs were excluded from the
Cox model (19).
Results
Patients. Recurrent VT/VF occurred in 229 patients
(54.4%), 62 (14.7%) had syncope. The mean (6SD) follow-up
period at our or an affiliated clinic was 26 6 18 months (Table
2). The actuarial tachycardia-free survival rate was 68%, 58%,
45% and 37% after 6, 12, 24 and 36 months, respectively; 76%,
66%, 52% and 43% of patients survived without ICD shocks,
and 96%, 90%, 85% and 81% survived without syncope after 6,
12, 24 and 36 months, respectively (Fig. 1).
Tachycardias that caused syncope were 240 6 67 beats/min,
and 96% were primarily .180 beats/min (Table 2). Only two
incapacitating events occurred during tachycardias that were
primarily slow (150 beats/min). Eighteen patients (29.0%) had
syncope during the first recurrence of VT. First VTs that
caused syncope were significantly faster than first VTs without
syncope (270 6 41 vs. 194 6 39 beats/min, p , 0.0001).
Once VT/VF had occurred, 81%, 76%, 68% and 62% of
patients remained free of syncope after 6, 12, 24 and 36
months, respectively. Once syncope had occurred, 76%, 68%,
64% and 56% of patients remained free of second syncope 6,
12, 24 and 36 months, respectively.
Most syncope (43.6%) occurred while the patients were at
rest, with 25.8% occurring during everyday activity (e.g.,
shopping, cycling, mowing) and 6.5% during some type of
sports activity (e.g., skiing, jogging, cycling). Except for two
Table 2. Tachyarrhythmias and Syncope During Follow-Up
Follow up (mo)
Mean 6 SD 26 6 18
Range 1–79
Recurrence of VT/VF 229 (54.4%)
VT/VF treated by ICD shocks 196 (46.6%)
Syncope 62 (14.7%)
Occurred with 1st VT 18 (29.0%)
Caused by 1st VT 18 (7.9%)
CL of VT causing syncope
(ms)
Mean 6 SD 251 6 56
Range 160–420
Physical activity before
syncope
Effort/strain 4 (6.5%)
Daily activity 9 (14.5%)
Standing 7 (11.3%)
Sitting 14 (22.6%)
Lying 13 (21.0%)
Not documented 15 (24.4%)
ICD therapy during 1st
syncope
VT below detection rate 1 (1.6%)
Nonsustained fast VT 1 (1.6%)
Effective ATP 2 (3.2%)
Ineffective ATP 1 effective
shock
2 (3.2%)
Acceleration during ATP 1
effective shock
6 (9.7%)
Effective 1st shock 34 (54.8%)
.1 shock for termination
of VT/VF
4 (6.5%)
Incessant or cluster of VT/
VF causing multiple
shocks
5 (8.0%)
Inadequate ICD therapy 2 (3.2%)
Unknown 5 (8.1%)
Change of therapy
Reduction of detection
time
6 (9.7%)
Reduction of charging time 8 (12.9%)
Change of zones to avoid
ATP for fast VTs
4 (6.5%)
Biphasic device to improve
defibrillation efficacy
2 (3.2%)
Class III AA 6 (9.7%)
Ablation 2 (3.2%)
Other 7 (11.3%)
No change of therapy 27 (43.5%)
Recurrent syncope 17 (4.0%)
Data presented are number (%) of patients, unless otherwise indicated.
AA 5 antiarrhythmic drug; other abbreviations as in Table 1.
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patients who died, only minor injuries occurred. One patient
had syncope while riding a bicycle. He was taking warfarin for
anticoagulation and died 2 weeks later because of cerebral
bleeding. Another patient had syncope while driving a car. He
died due to incessant VT shortly after syncope. An accident
was prevented by a frontseat passenger. No harm to others as
a result of incapacitating events has come to our attention.
Most syncope (54.8%) occurred despite immediate and
successful delivery of a first 34-J shock. In these cases, the
capacitor charging time was 9.4 6 2.7 s (range 6.1 to 15.7). In
6.5% of patients, a first shock failed. VTs that were initially
treated by antitachycardia pacing were a rare cause of syncope
(16.1%) and were frequently caused by acceleration of VT
during antitachycardia pacing (9.7%); 8.0% of syncope oc-
curred due to incessant or clusters of VTs. One syncope was
caused by a VT below the detection rate, one by a nonsus-
tained, fast VT. The cause of syncope remained unknown in
five patients, either because ICD stores were exhausted (n 5 2)
or no VT was documented at all (n 5 3). No cause for syncope
could be defined in the latter three patients despite a reduction
of the detection rate, Holter monitoring and tilt table testing.
In particular, no bradycardia or pacemaker-induced syncope
could be verified (Table 2).
Predictors of risk. Patients with a left ventricular ejection
fraction (LVEF) #40% had a significantly higher risk of
syncope than patients with an LVEF .40% (p 5 0.014): 95%,
87%, 82% and 75% of patients with a low LVEF remained free
of syncope, whereas 97%, 93%, 88% and 86% of patients with
a high LVEF survived free of syncope after 6, 12, 24 and 36
months, respectively (Fig. 2). In the Cox regression model, a
1% increase in LVEF implied a decrease of risk of syncope by
2% (Table 3).
Induction of fast VT (cycle length [CL] ,300 ms) during
baseline PVS indicated a syncope-free survival rate of 94%,
82%, 78% and 73%, whereas induction of no or slow VT or VF
indicated a syncope-free survival rate of 96%, 94%, 88% and
84% after 6, 12, 24 and 36 months, respectively (p 5 0.0438)
(Fig. 3). There was no significant difference between actuarial
syncope-free survival of patients with inducible slow VT/VF
and those with no inducible VT. Similar results could be
obtained from predischarge PVS with even higher significance
(p 5 0.0048). By Cox regression analysis, induction of a fast VT
during PVS indicated a 2.2-fold increase in risk (95% confi-
dence interval 1.3 to 3.7) (Table 3). The induced VT CL
significantly correlated with the recurrent VT CL: For baseline
PVS and first recurrent VT CL, R 5 10.4565, p , 0.0001; for
predischarge PVS, R 5 10.5456, p , 0.0001.
Patients with chronic AF had a significantly higher risk of
syncope than those with intermittent or no AF: 91%, 86% and
82% of patients without chronic AF survived free of syncope,
whereas only 84%, 74% and 48% of patients with chronic AF
remained free of syncope after 12, 24 and 36 months, respec-
tively (p 5 0.006) (Fig. 4). By multivariate Cox regression
analysis, the presence of chronic AF implied a 3.6-fold increase
in risk (95% confidence interval 1.8 to 7.4, p 5 0.0004) (Table
3).
For a low LVEF (#40%), documented chronic AF and fast
Figure 1. Survival free of syncope, appropriate ICD shock and VT/VF. Figure 2. Syncope-free survival and LVEF. In 11 patients, determina-
tion of LVEF was technically impossible or invalid.
Table 3. Stepwise Cox Regression of Risk of Syncope and Baseline
Characteristics of Patients*
Regression
Coefficient (b)
Exp(b) (95%
CI)
p
Value
LVEF 20.02 0.98 (0.96–0.99) 0.0155
Chronic AF 11.29 3.62 (1.77–7.39) 0.0004
Inducible fast VT
(CL ,300 ms)
10.78 2.17 (1.26–3.73) 0.0050
*Variables tested in a stepwise manner without significant influence on
hazard of syncope were age, gender, heart disease, functional class, documented
intermittent atrial fibrillation, arrhythmic history (ventricular tachycardia, car-
diac arrest), antiarrhythmic intervention (ablation, antitachycardia surgery), site
of infarction and bypass surgery in patients with coronary artery disease, type of
implantable cardioverter-defibrillator, number of zones programmed, detection
rate; discharge medication was excluded from analysis because it was dependent
on other variables. CI 5 confidence interval; other abbreviations as in Table 1.
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VT induced during predischarge test were assumed to be
predictors of risk of syncope. Patients with no risk factor
differed significantly from patients with one (p 5 0.0078) and
two risk factors (p 5 0.0002). Patients with two risk factors
showed a trend toward a higher risk of syncope than patients
with one risk factor (p 5 0.1078). If patients had no risk factor,
99%, 96%, 92% and 92% remained free of syncope, whereas
only 94%, 80%, 77% and 65% with two risk factors survived
free of syncope after 6, 12, 24 and 36 months, respectively (p 5
0.0002).
Nine patients had syncope despite the absence of any risk
predictor, three with CAD, two with dilated cardiomyopathy,
two with the long QT syndrome, one with no heart disease and
one with VF induced by coronary spasm. All had had cardiac
arrest at least once before ICD implantation.
Once patients had developed their first VT after ICD
implantation, predictors of risk of future syncope were the
occurrence of syncope during the first recurrence of VT and a
rapid heart rate during the first VT. A trend for higher risk in
patients with chronic AF, inducible fast VT and a low LVEF
remained (Table 4).
Antiarrhythmic medication at hospital discharge. Of 12
patients discharged with class I antiarrhythmic drugs, 10 had
recurrent VTs (mean CL of the first recurrent VTs was 311 6
61 ms), and none had syncope. The 75 patients discharged with
beta-adrenergic blocking agents, showed a trend toward reduc-
tion of risk of recurrent VT (p 5 0.083) and syncope (p 5
0.094) that was still visible after correction for other risk
factors. Of 32 patients discharged with amiodarone, 17 had
recurrent VTs (mean CL of the first VTs was 395 6 100 ms),
and only 3 had syncope. Actuarial syncope-free survival was
90% and 81% after 12 and 24 months, respectively. No syncope
occurred beyond the second year of follow up. In 59 patients
discharged with sotalol, the risk of syncope was not signifi-
cantly different from patients with other antiarrhythmic drugs
or no antiarrhythmic medication. The 22 patients discharged
with calcium antagonists had a higher risk of syncope than
patients without calcium antagonists (p 5 0.049). The actuarial
survival rate free of syncope was 96%, 91%, 86% and 80%
without and 96%, 83%, 76% and 63% with calcium antagonists
after 6, 12, 24 and 36 months, respectively. After correction for
AF, this difference remained but lost significance. Ninety-
seven percent, 94%, 91% and 86% of patients without digitalis
remained free of syncope, whereas only 95%, 87%, 81% and
76% of patients with digitalis (n 5 232) survived free of
syncope after 6, 12, 24 and 36 months, respectively (p 5 0.006).
Even after correction for LVEF and AF, this difference was
still present but was no longer significant (p 5 0.063).
Change of therapy after syncope. Of 62 patients with
syncope, therapy was not changed in 27 (43.5%). In eight
patients (12.8%), first shock energy was reduced to defibrilla-
tion threshold (DFT) plus a 10-J safety margin to shorten
Figure 3. Syncope-free survival and results of baseline ventricular
stimulation: patients in whom fast VTs (CL ,300 ms) were induced
versus patients who had no or only slow VT (CL $300 ms) induced or
in whom only VF was inducible.
Figure 4. Syncope-free survival and chronic (chron.) AF.
Table 4. Stepwise Cox Regression Analysis of Risk of Syncope After
First Ventricular Tachycardia/Atrial Fibrillation and Baseline
Characteristics of Patients*
Regression
Coefficient
(b)
Exp(b) (95%
CI)
p
Value
LVEF 20.01 0.99 (0.97–1.01) 0.1376
Chronic AF 10.73 2.07 (0.97–4.44) 0.0599
Inducible fast VT
(CL ,300 ms)
10.52 1.69 (0.97–2.92) 0.0619
CL of recurrent VT 20.01 0.99 (0.98–1.00) 0.0164
1st VT caused
syncope
11.36 3.88 (2.15–7.01) , 0.0001
*Variables tested in a stepwise manner without significant influence on
hazard of syncope were age, gender, heart disease, functional class, documented
intermittent atrial fibrillation, arrhythmic history (ventricular tachycardia, car-
diac arrest), antiarrhythmic intervention (ablation, antitachycardia surgery), site
of infarction and bypass surgery in patients with coronary artery disease, type of
implantable cardioverter-defibrillator, number of zones programmed, detection
rate; discharge medication was excluded from analysis because it was dependent
on other variables. Abbreviations as in Tables 1 and 3.
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capacitator charging time (Table 2). In six patients (9.7%),
detection time was reduced from 2.5 to 1 s to reduce therapy
time; in six patients (9.7%), a class III antiarrhythmic agent
was prescribed, and in four patients (6.5%), detection zones
were changed (i.e., the detection rate for primary shock
therapy was reduced from 200 to 180 beats/min). Recurrent
syncope occurred in three of six patients in whom detection
time was reduced, two of eight patients in whom first shock
energy was reduced and none of six patients in whom class III
antiarrhythmic agents were prescribed after first syncope. The
two patients with syncope after reduction of shock energy
needed a second shock for termination of tachycardia; 5 of the
27 patients with no change of therapy had recurrent syncope.
Discussion
Occurrence of syncope. Several studies have analyzed the
occurrence of incapacitating symptoms in patients with an ICD
(20–23). Grimm et al. (21) found no, mild and severe symp-
toms (presyncope/syncope) preceding spontaneous ICD
shocks in 20 (30%), 33 (49%) and 27 (40%) patients, respec-
tively, with electrocardiographically documented VT or VF
during a follow-up period of 24 6 20 months. Because there is
no clear-cut definition of presyncope, contrary to that study we
did not include presyncope in our analysis to avoid overesti-
mation of incapacitation during ICD treatment. The fact that
in one study (5), only 10.5% of ICD discharges were found to
cause accidents, and all fatal accidents were due to syncope,
favors this approach (5).
In a study by Kou et al. (22) in 180 patients with an ICD, the
incidence of unconsciousness was 9% after a follow-up period
of 16 6 12 month, which is close to our event rate after 1 year.
Kou et al. seem to underestimate the occurrence of severe
incapacitating events, possibly because of a shorter follow-up
period.
Our data suggest that occurrence of syncope is a frequent
clinical problem in patients with an ICD. More than one-third
of patients with recurrent VT will have at least one episode of
syncope, and almost half of these (44%) will have a second
episode during 3 years of follow-up. The risk of syncope proved
to be highest during the first year of ICD therapy (10%) and
decreased in the second year (5%) but remained considerable
in the third year (4%). Most syncope occurred shortly after the
first ICD intervention.
Except for two patients who died, only minor injuries
occurred. One patient was taking warfarin for anticoagulation
and died of cerebral bleeding after a bicycle accident; the other
died of incessant VT shortly after syncope. No harm to others
has come to our attention.
Predictors of risk. Two studies so far have failed to dem-
onstrate that prediction of incapacitating events may be feasi-
ble: Kou et al. (22) found that the absence of syncope during
one ICD shock did not predict the absence of syncope during
subsequent shocks. Accordingly, in our study only 29% of
syncope occurred with the first ICD therapy. In the study by
Kou et al., syncope could not be predicted by age, gender,
history of syncope, left ventricular function, type of underlying
heart disease, electrophysiologic findings, rate of VT, antiar-
rhythmic medications or type of pulse generator implanted,
possibly because of smaller patient numbers, a lower event rate
and a shorter follow-up period.
Similarly, Schoels et al. (23) found that LVEF was signifi-
cantly lower in 12 patients with than in 89 patients without
syncope during a follow-up period of 19.3 6 10.5 months
(LVEF 32 6 14% vs. 41 6 13%). However, the predictive
value was low because there was great overlap between LVEF
in patients with and without syncope (23).
In contrast, our study shows that chronic AF, which Kou et
al. (22) and Schoels et al. (23) did not analyze, a low LVEF,
fast VT induced during either baseline or predischarge PVS
indicate an increased risk of syncope. The predictive value of
left ventricular function may be due to the finding that a
depressed LVEF indicates a higher risk of recurrent VT
(24,25). The overlap between the LVEF of patients with and
without syncope in the study by Schoels et al. (23) may be due
to the presence or absence of other risk factors.
Patients with fast VT (CL ,300 ms) induced by PVS had a
higher risk of syncope during follow-up than patients in whom
no or slow VT or VF (the latter may be considered nonspe-
cific) had been induced. Most incapacitating events occurred in
patients with inducible fast VT. The predictive value of PVS
may be due to the positive correlation between CLs of induced
and recurrent VT demonstrated in the present study. However,
patients with slow, monomorphic VT are at considerable risk
for fast VT or VF during follow-up (3). Previous studies did
not consider PVS predictive of syncope, possibly because they
did not differentiate between slow and fast VT.
Patients with chronic AF had a significantly higher risk of
syncope even after correction for LVEF and the results of
PVS, possibly because they have a hemodynamic disadvantage
during VT and thus are slow to recover from tachycardia after
ICD therapy. Furthermore, it has been demonstrated (26) that
patients with AF may also be predisposed to an abnormal
neural response during both sinus rhythm and arrhythmia.
The absence of all three risk factors in 129 patients signified
a syncope-free survival rate of 93% after 18 months and 92%
after 36 months. Four of nine patients in the “no-risk” group
had a rare condition, such as the long QT syndrome (n 5 2),
VF triggered by coronary spasm (n 5 1) or idiopathic VF (n 5
1). Therefore, predictors of risk should not or only with caution
be applied to patients with a rare condition.
Prevention. Most tachycardias that caused syncope were
primarily fast. First shocks were successful in 54.8% of pa-
tients, implying that the risk of syncope can be decreased if the
tachycardia rate is slowed or the duration of therapy for fast
VT (detection time plus charging time) is shortened. Charging
time in patients in whom a first shock terminated the tachy-
cardia was 9.4 6 2.7 s. Syncope still occurred with a charging
time as low as 6.1 s. A charging time ,6 s would imply a DFT
well below 15 J if a 10-J margin between shock energy and
DFT is to be maintained. Maintaining such a DFT seems to be
feasible with modern devices and electrode configurations
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(27). A low DFT should be sought and used as an implantation
criterion, especially in patients with a high risk of syncope.
Shock therapy is usually applied to VTs .200 to 220 beats/min.
Therapy time may also be reduced in some cases of fast VT if
antitachycardia pacing is applied to fast VT during charging.
Antiarrhythmic therapy in addition to ICD treatment may
be the approach of choice. The favorable outcome of patients
with class I antiarrhythmic therapy and amiodarone who
experienced few episodes of syncope, even though many of
them had recurrent but mainly slow tachycardias, may favor
this approach. None of the six patients with class III antiar-
rhythmic therapy prescribed after their first syncope had
recurrent syncope. However, the prescription of amiodarone
and some class I antiarrhythmic drugs may cause an increase in
DFT and expose the patient to an increased risk of syncope
because of the need to increase shock energy and charging
time (28). Furthermore, Kou et al. (29) found that untested
antiarrhythmic drugs or those previously demonstrated to be
ineffective during electropharmacologic testing failed to re-
duce the probability of ICD discharges over the short term
(mean 14 months) in 74 patients and even seemed to increase
the risk of syncope during ICD discharge. Because the results
of PVS appeared to predict the risk of syncope, serial drug
testing may help to identify the appropriate antiarrhythmic
therapy. The target of drug therapy in patients with syncope
should be to induce no or only slow VTs.
Beta-adrenergic blocking agents showed a tendency to
reduce recurrent VT and syncope, in line with the suggestion
that beta-blockers decrease the frequency of ICD therapy
delivery and may also improve general outcome (30). The
favorable effect of beta-blockers may also hint at the impor-
tance of autonomic tone for the occurrence of VT and syncope.
Dangerous occupations and driving restrictions. Most
studies suggest a ban on driving for a certain event-free period
during follow-up after ICD implantation or tachycardia (4,6,8–
11). Some working groups have suggested (4) estimating the
risk of fatal accidents on the basis of a “worst case” scenario;
that is, all VTs in patients with an ICD may compromise
consciousness and result in an accident. However, according to
Curtis (5), only 10.5% of shocks delivered during driving
resulted in an accident. Therefore, the risk of any VT or shock
may overestimate the risk of a patient with an ICD causing an
accident. The reported risk of accidents is ;25/100,000
patient-years, with a fatality rate of 7.5/100,000 patient-years
(5). In the present report, private and commercial driving were
not considered separately. All fatal accidents were related to
patient unconsciousness. We therefore suggest estimating pa-
tients fitness to drive on the basis of the risk of syncope.
Based on the formula TD 3 V 3 SCI 3 Ac, suggested by
the Canadian Cardiovascular Society (where TD is the time
behind the wheel [1 h/day for private, 6 h for commercial
driving], V a constant based on the type of vehicle driven [0.28
for private, 1.0 for commercial driving], SCI the risk of
unconsciousness and Ac the risk of producing a fatal or
injury-producing accident [Ac 5 0.02]), we estimated the
number of extra accidents/100,000 patient-years based on the
risk of syncope for patients driving privately [commercially], if
driving were not prohibited until first syncope (31). All patients
with an ICD would cause 2.3 [50] accidents/100,000 patients in
the first, 1.2 [25] in the second and 0.9 [20] in the third year.
One hundred thousand patients with no risk factor (no
chronic AF, LVEF .40%, no inducible fast VT) would cause
;0.9 [20] accidents in the first and second years and ,0.2 [5]
accidents in the third year; 100,000 patients with an LVEF
,40% would cause 3 [65] accidents in the first, 1.2 [25] in the
second and 1.5 (35) in the third year. The numbers for patients
with chronic AF would be 3.7 [65] in the first, 2.3 [50] in the
second and 6 [120] in the third year. For patients with inducible
fast VT, the number of extra accidents would be 3.3 [70] in
first, 0.9 [20] in the second and 1.2 [25] in the third year.
During the first, second and third years after a first VT, 100,000
patients would cause 3.3 [70], 1.9 [40] and 1.4 [30] accidents,
respectively. After the first syncope, the numbers are 7.5 [160]
for the first, 0.9 [20] for the second and 1.9 [40] for the third
year.
If society will tolerate 10 extra accidents/100,000 patient-
years, all patients could be allowed to drive privately, and
patients without any risk predictor could even be allowed to
drive commercially after 2 years of event-free follow-up until a
first syncope occurs. If only 1 extra accident/100,000 patient-
years is acceptable, then commercial driving could not be
allowed at all, and the following patients should not drive
privately: patients with chronic AF at any time and patients
with a low LVEF and fast inducible VTs for at least 1 year.
After the first VT, patients should not drive for 2 years and
after syncope for 1 year. With these recommendations, ;1.2
extra accidents would occur/100,000 patient-years due to syn-
cope in patients with an ICD.
Major restrictions of the study. Although patients were
explicitly asked at every follow-up visit whether syncope or
related symptoms had occurred, some episodes of syncope may
not have come to our attention because patients may not
remember or report episodes of syncope for various reasons.
However, follow-up has been very close (3-month intervals)
and patients, relatives and witnesses have been interviewed.
Patients with many different ICD systems and generations,
both monophasic and biphasic, were included in this study.
Nowadays, with biphasic ICDs that allow a lower DFT and
first-shock energy, the risk of syncope may be lower than that
assumed in this study.
Conclusions. Syncope occurs frequently in patients with an
ICD. Major predictors of syncope are a low LVEF, inducible
fast VT and chronic AF. After the first recurrence of VT,
major risk predictors of future syncope are a fast heart rate or
syncope at first VT. Recommendations for patients’ daily lives
should be based on risk stratification and follow up.
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